Integrated BioPharma (OTCMKTS:INBP – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.02) EPS for the quarter, Zacks reports. The firm had revenue of $9.91 million for the quarter. Integrated BioPharma had a negative net margin of 6.48% and a negative return on equity of 14.78%.
Integrated BioPharma Price Performance
OTCMKTS:INBP remained flat at $0.17 during trading hours on Friday. The firm has a market cap of $5.12 million, a P/E ratio of -1.65 and a beta of 0.49. Integrated BioPharma has a 1-year low of $0.14 and a 1-year high of $0.42. The firm has a 50 day moving average of $0.17 and a two-hundred day moving average of $0.22.
About Integrated BioPharma
Integrated BioPharma, Inc. is a healthcare and consumer-products company that manufactures, distributes and markets vitamins, nutritional supplements, herbal products and specialty pharmaceutical products. Its activities include producing health and wellness products for its own brands as well as providing contract manufacturing services for other businesses. The company’s product offerings have included dietary supplements, botanical and herbal formulations, vitamins, minerals and other nutrition-related products.
Read More
- Five stocks we like better than Integrated BioPharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
